CoChat
Sign Up
Cited by 106

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Thermosensitive hexanoyl glycol chitosan-based ocular delivery system for glaucoma therapy

Cho, Ik Sung, Park, Chun Gwon, Huh, Beom Kang, Cho, Myeong Ok, Khatun, Zehedina, Li, Zhengzheng, Kang, Sun-Woong, Choy, Young Bin, Huh, Kang Moo·2016·Acta Biomaterialia
DOI 10.1016/j.actbio.2016.05.011
Open this paper in CoChat — free account

Abstract

Unlabelled Conventional eye drops quickly move away from the surface of the eye; as a result, ocular bioavailability is very limited. To overcome this issue, we developed a thermosensitive hexanoyl glycol chitosan (HGC) as a carrier for topical drug delivery to the eye. Here, we modulated the degree of N-hexanoylation to control the thermogelling behavior and prepared a new ocular formulation of HGC for glaucoma therapy. The viscosity of the aqueous formulation sharply and significantly increases at body temperature. The results from cytotoxicity evaluation showed that HGC is non-toxic at up to 1.25wt.%. In vivo experiments demonstrated that HGC is maintained on the preocular surface for a comparatively longer period of time due to its enhanced viscosity at body temperature. As a result, when brimonidine was loaded, the formulation exhibited attractive bioavailability properties as well as more prolonged period of lowered intra-ocular pressure (14h) compared with Alphagan P, the marketed medication for brimonidine treatment. Statement of significance In this manuscript, hexanoyl glycol chitosan (HGC) was synthesized by the N-hexanoylation of glycol chitosan. We have observed that an aqueous solution of HGC exhibited a dramatic increase in viscosity as the temperature increased. The HGC-based formulation showed prolonged retention on the preocular surface and enhanced drug availability and efficacy.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.actbio.2016.05.011

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 45

  1. Kaur, 2004, Vesicular systems in ocular drug delivery: an overview, Int. J. Pharm., 269, 1, 10.1016/j.ijpharm.2003.09.016 · DOI
  2. Lang, 1995, Ocular drug delivery conventional ocular formulations, Adv. Drug Del. Rev., 16, 39, 10.1016/0169-409X(95)00012-V · DOI
  3. Le Bourlais, 1998, Ophthalmic drug delivery systems—recent advances, Prog. Retinal Eye Res., 17, 33, 10.1016/S1350-9462(97)00002-5 · DOI
  4. He, 2011, Doxycycline and hydroxypropyl-β-cyclodextrin complex in poloxamer thermal sensitive hydrogel for ophthalmic delivery, Acta Pharm. Sin. B, 1, 254, 10.1016/j.apsb.2011.10.004 · DOI
  5. Gurtler, 1995, Ocular availability of gentamicin in small animals after topical administration of a conventional eye drop solution and a novel long acting bioadhesive ophthalmic drug insert, Pharm. Res., 12, 1791, 10.1023/A:1016242528222 · DOI
  6. Bhowmik, 2013, Effect of xanthan gum and guar gum on in situ gelling ophthalmic drug delivery system based on poloxamer-407, Int. J. Biol. Macromol., 62, 117, 10.1016/j.ijbiomac.2013.08.024 · DOI
  7. Järvinen, 1995, Ocular absorption following topical delivery, Adv. Drug Del. Rev., 16, 3, 10.1016/0169-409X(95)00010-5 · DOI
  8. Bucolo, 2012, Ocular drug delivery: a clue from nanotechnology, Front. Pharmacol., 3, 1, 10.3389/fphar.2012.00188 · DOI
  9. Srividya, 2001, Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system, J. Controlled Release, 73, 205, 10.1016/S0168-3659(01)00279-6 · DOI
  10. Kirchhof, 2015, Hydrogels in ophthalmic applications, Eur. J. Pharm. Biopharm., 95, 227, 10.1016/j.ejpb.2015.05.016 · DOI
  11. Lavik, 2011, Novel drug delivery systems for glaucoma, Eye, 25, 578, 10.1038/eye.2011.82 · DOI
  12. Edsman, 1998, Rheological evaluation of poloxamer as an in situ gel for ophthalmic use, Eur. J. Pharm. Sci., 6, 105, 10.1016/S0928-0987(97)00075-4 · DOI
  13. Liu, 2006, Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin, Int. J. Pharm., 315, 12, 10.1016/j.ijpharm.2006.01.029 · DOI
  14. Robinson, 1995, Bioadhesive and phase-change polymers for ocular drug delivery, Adv. Drug Del. Rev., 16, 45, 10.1016/0169-409X(95)00013-W · DOI
  15. Moon, 2012, Temperature-responsive compounds as in situ gelling biomedical materials, Chem. Soc. Rev., 41, 4860, 10.1039/c2cs35078e · DOI
  16. Park, 2011, Biodegradable thermogels, Acc. Chem. Res., 45, 424, 10.1021/ar200162j · DOI
  17. Musumeci, 2013, Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits, Int. J. Pharm., 440, 135, 10.1016/j.ijpharm.2012.10.014 · DOI
  18. El-Salamouni, 2015, Effect of sterilization on the physical stability of brimonidine-loaded solid lipid nanoparticles and nanostructured lipid carriers, Int. J. Pharm., 496, 976, 10.1016/j.ijpharm.2015.10.043 · DOI
  19. Xi, 2014, Evaluation of an injectable thermosensitive hydrogel as drug delivery implant for ocular glaucoma surgery, PLoS ONE, 9, 10.1371/journal.pone.0100632 · DOI
  20. Wei, 2002, Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies, J. Controlled Release, 83, 65, 10.1016/S0168-3659(02)00175-X · DOI
  21. Hsiue, 2002, Preparation of controlled release ophthalmic drops, for glaucoma therapy using thermosensitive poly-N-isopropylacrylamide, Biomaterials, 23, 457, 10.1016/S0142-9612(01)00127-2 · DOI
  22. Jeong, 1997, Biodegradable block copolymers as injectable drug-delivery systems, Nature, 388, 860, 10.1038/42218 · DOI
  23. El-Kamel, 2002, In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate, Int. J. Pharm., 241, 47, 10.1016/S0378-5173(02)00234-X · DOI
  24. Kempe, 2012, In situ forming implants—an attractive formulation principle for parenteral depot formulations, J. Controlled Release, 161, 668, 10.1016/j.jconrel.2012.04.016 · DOI
  25. Felt, 1999, Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention, Int. J. Pharm., 180, 185, 10.1016/S0378-5173(99)00003-4 · DOI
  26. Lee, 1995, Blood compatibility and biodegradability of partially N-acylated chitosan derivatives, Biomaterials, 16, 1211, 10.1016/0142-9612(95)98126-Y · DOI
  27. Diez-Sales, 2007, Acyclovir delivery matrices based on poly (ethylene glycol)/chitosan semi-interpenetrating networks, J. Pharm. Sci., 96, 1653, 10.1002/jps.20825 · DOI
  28. Sogias, 2008, Why is chitosan mucoadhesive?, Biomacromolecules, 9, 1837, 10.1021/bm800276d · DOI
  29. Cheng, 2014, Sustained delivery of latanoprost by thermosensitive chitosan–gelatin-based hydrogel for controlling ocular hypertension, Acta Biomater., 10, 4360, 10.1016/j.actbio.2014.05.031 · DOI
  30. Varshosaz, 2008, Designing of a thermosensitive chitosan/poloxamer in situ gel for ocular delivery of ciprofloxacin, TODDJ, 2, 61, 10.2174/1874126600802010061 · DOI
  31. Cao, 2007, Poly (N-isopropylacrylamide)–chitosan as thermosensitive in situ gel-forming system for ocular drug delivery, J. Controlled Release, 120, 186, 10.1016/j.jconrel.2007.05.009 · DOI
  32. Li, 2013, Preparation and characterization of glycol chitin as a new thermogelling polymer for biomedical applications, Carbohydr. Polym., 92, 2267, 10.1016/j.carbpol.2012.11.068 · DOI
  33. Bucolo, 2015, Controversies in glaucoma: current medical treatment and drug development, Curr. Pharm. Des., 21, 4673, 10.2174/1381612821666150909095553 · DOI
  34. Knight, 2007, Structure, depolymerization, and cytocompatibility evaluation of glycol chitosan, J. Biomed. Mater. Res., Part A, 83, 787, 10.1002/jbm.a.31430 · DOI
  35. Loh, 2007, New biodegradable thermogelling copolymers having very low gelation concentrations, Biomacromolecules, 8, 585, 10.1021/bm0607933 · DOI
  36. Jeong, 2003, Phase transition of the PLGA-g-PEG copolymer aqueous solutions, J. Phys. Chem. B, 107, 10032, 10.1021/jp027339n · DOI
  37. Lee, 2010, Thermo-sensitive, injectable, and tissue adhesive sol–gel transition hyaluronic acid/pluronic composite hydrogels prepared from bio-inspired catechol-thiol reaction, Soft Matter, 6, 977, 10.1039/b919944f · DOI
  38. Park, 2014, Nanostructured mucoadhesive microparticles for enhanced preocular retention, Acta Biomater., 10, 77, 10.1016/j.actbio.2013.08.026 · DOI
  39. Savolainen, 2003, A novel D2-dopaminergic and α2-adrenoceptor receptor agonist induces substantial and prolonged IOP decrease in normotensive rabbits, J. Pharm. Pharmacol., 55, 789, 10.1211/002235703765951393 · DOI
  40. Yang, 2012, Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration, ACS Nano, 6, 7595, 10.1021/nn301873v · DOI
  41. Bhagav, 2010, Development and validation of stability indicating UV spectrophotometric method for the estimation of brimonidine tartrate in pure form, formulations and preformulation studies, Der Pharmacia Lettre, 2, 106
  42. Singh, 2010, Development and evaluation of novel polymeric nanoparticles of brimonidine tartrate, Curr. Drug Del., 7, 244, 10.2174/156720110791561008 · DOI
  43. Gong, 2009, Thermosensitive PEG–PCL–PEG hydrogel controlled drug delivery system: sol–gel–sol transition and in vitro drug release study, J. Pharm. Sci., 98, 3707, 10.1002/jps.21694 · DOI
  44. Jeong, 2000, Thermogelling biodegradable polymers with hydrophilic backbones: PEG-g-PLGA, Macromolecules, 33, 8317, 10.1021/ma000638v · DOI · Paper page
  45. Chung, 2002, Sol-gel transition temperature of PLGA-g-PEG aqueous solutions, Biomacromolecules, 3, 511, 10.1021/bm0156431 · DOI

Cited by

Sorted by citations

See all 106

Metadata

Authors
Cho, I. S., Park, C. G., Huh, B. K., Cho, M. O., Khatun, Z., Li, Z., Kang, S.-W., Choy, Y. B., & Huh, K. M.
Venue
Acta Biomaterialia
Publisher
Elsevier BV
Published
2016-07
Volume
39
Pages
124-132
ISSN
1742-7061
DOI
10.1016/j.actbio.2016.05.011
Cited by
106
References
1
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review